| Literature DB >> 25909773 |
Philip K Frykman1, Agneta Nordenskjöld2, Akemi Kawaguchi3, Thomas T Hui4, Anna L Granström2, Zhi Cheng5, Jie Tang6, David M Underhill7, Iliyan Iliev7, Vince A Funari6, Tomas Wester2.
Abstract
Development of potentially life-threatening enterocolitis is the most frequent complication in children with Hirschsprung disease (HSCR), even after definitive corrective surgery. Intestinal microbiota likely contribute to the etiology of enterocolitis, so the aim of this study was to compare the fecal bacterial and fungal communities of children who developed Hirschsprung-associated enterocolitis (HAEC) with HSCR patients who had never had enterocolitis. Eighteen Hirschsprung patients who had completed definitive surgery were enrolled: 9 had a history of HAEC and 9 did not. Fecal DNA was isolated and 16S and ITS-1 regions sequenced using Next Generation Sequencing and data analysis for species identification. The HAEC group bacterial composition showed a modest reduction in Firmicutes and Verrucomicrobia with increased Bacteroidetes and Proteobacteria compared with the HSCR group. In contrast, the fecal fungi composition of the HAEC group showed marked reduction in diversity with increased Candida sp., and reduced Malassezia and Saccharomyces sp. compared with the HSCR group. The most striking finding within the HAEC group is that the Candida genus segregated into "high burden" patients with 97.8% C. albicans and 2.2% C. tropicalis compared with "low burden" patients 26.8% C. albicans and 73% C. tropicalis. Interestingly even the low burden HAEC group had altered Candida community structure with just two species compared to more diverse Candida populations in the HSCR patients. This is the first study to identify Candida sp. as potentially playing a role in HAEC either as expanded commensal species as a consequence of enterocolitis (or treatment), or possibly as pathobioants contributing to the pathogenesis of HAEC. These findings suggest a dysbiosis in the gut microbial ecosystem of HAEC patients, such that there may be dominance of fungi and bacteria predisposing patients to development of HAEC.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25909773 PMCID: PMC4409062 DOI: 10.1371/journal.pone.0124172
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patient Characteristics: HSCR Only.
| Subject ID | Sex | Age at stool collection (yr) | Location of TZ | Diet | Abx | Probiotics | Type | Duration (months) | 30 day compl | Chr. anomalies | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Breast milk | Duration (months) | Formula | ||||||||||
| 01–0003 | M | 3.3 | RS | + | 3 | + | N | Y | LB | 9 | - | - |
| 01–0006 | M | 5.3 | TV | - | + | N | N | - | - | - | ||
| 02–0035 | M | 0.4 | RS | + | 5 | - | N | Y | Lr | 4 | - | Ts 21 |
| 02–0036 | M | 0.8 | RS | + | 9 | - | N | Y | Lr | 6 | - | - |
| 02–0040 | M | 0.2 | RS | - | + | N | Y | Lr | Unk | - | - | |
| 03–0004 | M | 8 | RS | + | 12 | + | N | N | - | - | - | |
| 04–0003 | M | 2.3 | RS | - | + | N | N | - | - | - | ||
| 04–0004 | M | 1.9 | RS | + | Unk | + | N | N | - | - | - | |
| 04–0007 | F | 2.3 | RS | - | + | N | N | - | - | - | ||
| 03–0003 | M | 3.2 | DC | - | + | Y | N | - | IH | - |
aSample ID and site identification: 01—Cedars-Sinai Medical Center, Los Angeles, California; 02- Karolinska Institute, Stockholm, Sweden; 03—Children’s Hospital Los Angeles, Los Angeles, California; 04—Children’s Hospital of Oakland, Oakland, California.
# This subject was excluded from analysis because this patient had an ileostomy at the time of stool collection.
bLocation of TZ: location of transition zone from normal to aganglionic bowel. RS = rectosigmoid colon; DC = descending colon; TV = transverse colon.
cDiet: Diet in the first year of life
dUnk = unknown
eAbx: Antibiotics received within the 2 months prior to stool collection for this analysis.
* = Metronidazole
fProbiotics: LB = lactobacillus sp. and bifidobacterium sp. combined; Lr = Lactobacillus reuteri; LG = Lactobacillus GG.
g30-day compl: Complications occurring within 30 days of the pull-through operation. IH = internal hernia requiring surgical intervention requiring intestinal resection and ileostomy creation.
hChr. Anomalies: Chromosomal or known genetic mutations. Ts 21 = Trisomy 21
Patient Characteristics: HAEC.
| Subject ID | Sex | Age at stool collection (yr) | Location of TZ | Diet | Abx | Probiotics | Type | Duration (months) | 30 day compl | Chr. anomalies | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Breast milk | Duration (months) | Formula | ||||||||||
| 02–0037 | M | 1.7 | RS | + | 6 | + | Y | Y | Lr | 6 | HAEC | Ts 21 |
| 02–0038 | M | 5 | RS | - | + | N | Y | Lr | Unk | - | - | |
| 03–0001 | F | 3.5 | RS | - | + | Y | N | - | - | SC | ||
| 03–0005 | M | 2 | RS | + | 24 | - | N | N | - | - | - | |
| 03–0006 | M | 7.6 | RS | - | + | Y | N | - | HAEC | - | ||
| 03–0007 | M | 5.1 | RS | + | 3 | + | N | N | - | - | - | |
| 03–0008 | M | 3.1 | RS | - | + | N | Y | LG | 0.5 | - | Ts 21 | |
| 03–0010 | M | 3.7 | RS | + | 1.5 | + | N | N | - | HAEC | - | |
| 04–0005 | M | 1.2 | Il | + | 12 | Unk | N | N | - | - | - | |
| 02–0039 | M | 0.5 | RS | - | + | Y | Y | Lr | 6 | AS | - |
aSample ID and site identification: 01—Cedars-Sinai Medical Center, Los Angeles, California; 02- Karolinska Institute, Stockholm, Sweden; 03—Children’s Hospital Los Angeles, Los Angeles, California; 04—Children’s Hospital of Oakland, Oakland, California.
# This subject was excluded from analysis because he had active HAEC at the time of stool collection.
bLocation of TZ: location of transition zone from normal to aganglionic bowel. RS = rectosigmoid colon; Il = ileum.
cDiet: Diet in the first year of life
dUnk = unknown
eAbx: Antibiotics received within the 2 months prior to stool collection for this analysis.
* = Metronidazole;
** = Penicillin prophylaxis daily for sickle cell disease.
fProbiotics: LB = lactobacillus sp. and bifidobacterium sp. combined; Lr = Lactobacillus reuteri; LG = Lactobacillus GG.
g30-day compl: Complications occurring within 30 days of the pull-through operation. IH = internal hernia requiring surgical intervention requiring intestinal resection and ileostomy creation. HAEC = Hirschsprung-associated enterocolitis. AS = anastomotic stricture requiring dilatation.
hChr. Anomalies: Chromosomal or known genetic mutations. Ts 21 = Trisomy 21; SC = Sickle cell disease.
Fig 1Bacterial phyla in HSCR and HAEC patients.
A,16S rRNA gene sequence of fecal bacteria of nine HSCR patients and nine HAEC patients. The pie charts show average relative abundance of five major phyla and six subdominant phyla (summarized as “All others”). B, histograms demonstrating the phyla level bacterial composition of individual subjects with HSCR and HAEC. Individual subject numbers are labeled on the X axis and expressed as relative OTU abundance per each subject. Colors were assigned for each of the 11 detected phyla with the scheme at the right side.
Fig 2Fungal genera of HAEC patients have increased Candida sp. abundance compared with HSCR patients.
A, Genera level distribution of fungi in nine HSCR patients and eight HAEC patients expressed as OTU abundance of 18S ITS-1 sequences (upper panel). Candida species composition in HSCR and HAEC patients (lower panel). B, Histograms demonstrating the fungal genera composition of individual subjects with HSCR and HAEC. Individual subject numbers are labeled on the X axis and expressed as relative OTUs abundance per each subject. Seventy-four different genera were identified by ITS-1 sequencing. The histogram shows 13 most abundant genera, unclassified genera, and 61 infrequent genera being summarized as “All others”.
Fig 3Quantitative PCR of Candida albicans.
The quantitation of C. albicans by quantitative PCR on total fecal DNA from HSCR and HAEC patients.
Fig 4Candida albicans and tropicalis OTU abundance by phenotype.
A, The OTU abundance of Candida in feces of HSCR and HAEC patients. Three out of eight HAEC patients showed very elevated Candida OTU’s. B, relative distribution of C. albicans to C. tropicalis in the “high burden” patients compared with the “low burden” patients. Comparisons between each group using t-test are noted. There was no significant difference between the HSCR and HAEC-Candida low burden groups.